Corvus Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Ph…

Biotechnology
US, Burlingame [HQ]
Growth Rates · Payout · Yield

Dividends Over Time

  • Records
  • Forecasts [Soon]
Growth Rates
% YoY
% 3Yr
% 5Yr
% 10Yr
Key Metrics
- -% TTM Yield
- - Average Days Gap
Series
% - - Yield
0.00% Payout Ratio
Cash Amount Pay Date
Cash Amount Pay Date
End of CRVS's Analysis
CIK: 1626971 CUSIP: 221015100 ISIN: US2210151005 LEI: - UEI: -
Secondary Listings
CRVS has no secondary listings inside our databases.